Ingenia Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	7,419	-	3,531
Revenue Growth	-	-	-
Gross Profit	7,419	-	3,531
Selling, General & Admin	7,726	6,965	5,620
Research & Development	24,864	25,891	8,246
Other Operating Expenses	30.66	52.46	141.86
Operating Expenses	32,923	33,192	14,062
Operating Income	-25,503	-33,192	-10,532
Interest Expense	-179.31	-179.31	-48.88
Interest & Investment Income	136.91	136.91	80.56
Currency Exchange Gain (Loss)	-8.02	-8.02	-5.01
Other Non Operating Income (Expenses)	-3,618	-0.82	9.65
EBT Excluding Unusual Items	-29,172	-33,243	-10,496
Gain (Loss) on Sale of Investments	4,635	4,635	40,648
Gain (Loss) on Sale of Assets	-	-	-1
Pretax Income	-24,537	-28,609	30,151
Income Tax Expense	-2,160	-2,160	8,693
Net Income	-22,377	-26,448	21,458
Net Income to Common	-22,377	-26,448	21,458
Net Income Growth	-	-	-
Shares Outstanding (Basic)	28	14	12
Shares Outstanding (Diluted)	28	14	42
Shares Change	-	-68.05%	-
EPS (Basic)	-807.42	-1948.00	1760.00
EPS (Diluted)	-807.42	-1948.00	505.00
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-18,503	-32,042	-20,056
Free Cash Flow Per Share	-667.64	-2360.00	-472.00
Gross Margin	100.00%	-	100.00%
Operating Margin	-343.75%	-	-298.31%
Profit Margin	-301.60%	-	607.78%
Free Cash Flow Margin	-249.39%	-	-568.06%
EBITDA	-24,322	-32,151	-10,227
EBITDA Margin	-	-	-289.66%
D&A For EBITDA	1,181	1,041	305.18
EBIT	-25,503	-33,192	-10,532
EBIT Margin	-	-	-298.31%
Effective Tax Rate	-	-	28.83%